Generic drugs are just as effective as brand names. However, generics don’t always translate to lower costs. Certain generics remain more expensive than some members can afford and are not always available. We want to be part of the solution.
To help address these issues, IngenioRx’s parent company has joined with Civica Rx. This non-profit organization aims to create competition in the generic drug market and drive down prices. The new partnership, called CivicaScript, will initially focus on the development of 6 to 10 common but high-priced generic drugs that treat a variety of health conditions. The new generics may appear on the market as early as 2022.
To read more about this new partnership, click the press release link below.